Compounded Tirzepatide

Tirzepatide is a dual-action medication that combines GLP-1 and GIP receptor activation to help regulate appetite, stabilize blood sugar, and support steady, clinically proven weight loss. It works by mimicking two natural hormones in the body, helping you feel fuller sooner and stay satisfied longer—making healthy choices easier and reducing the urge to overeat.

At AltrX, tirzepatide is offered in personalized programs designed to match your goals and your body's unique response. Guided by licensed clinicians through convenient telehealth care, your treatment plan adjusts as you progress, giving you a safe, effective, and science-driven approach to long-term weight management.

While both are effective for weight loss, tirzepatide has a dual mechanism—activating both GLP-1 and GIP receptors—compared to semaglutide's single GLP-1 pathway. Clinical trials show tirzepatide users lost an average of 15-22% of body weight versus 12-15% with semaglutide.

Tirzepatide may offer enhanced metabolic benefits due to its dual action, but individual response varies. Your clinician will help determine which medication aligns best with your health profile, goals, and tolerance.

Tirzepatide activates both GLP-1 and GIP receptors—a dual-hormone approach. GLP-1 reduces appetite and slows digestion, while GIP enhances insulin response and may improve fat metabolism. Together, they create synergistic effects on weight loss and metabolic health.

This dual mechanism addresses multiple pathways simultaneously—appetite regulation, blood sugar control, energy expenditure, and fat storage—resulting in more comprehensive metabolic support than single-hormone medications.

Similar to other GLP-1 medications, most users experience significantly reduced appetite and cravings within the first week. Meals become more satisfying with smaller portions, and the constant urge to snack tends to fade naturally.

Initial side effects may include mild nausea, digestive changes, or temporary fatigue—typically resolving within 2-4 weeks. The dual-action mechanism may provide more sustained energy throughout the day. Dosing begins low and increases gradually to optimize comfort and effectiveness.

Administration: Once-weekly subcutaneous injection (abdomen, thigh, or upper arm)
Dosing: Starts at 2.5mg weekly for 4 weeks, increasing by 2.5mg increments every 4 weeks based on response, up to 15mg weekly
Storage: Refrigerate before first use; can be kept at room temperature for up to 21 days after opening
Compounded by: Licensed U.S.-based compounding pharmacies following FDA guidelines